Battling regional (stage III) lung cancer: Bumpy road of a cancer survivor in the immunotherapy age

Zhonglin Hao, Paul Biddinger, Carsten Schroeder, Khurram Tariq

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A 58-year-old woman, a heavy smoker, was diagnosed with stage III squamous cell lung cancer. She was treated with concurrent chemotherapy and radiotherapy, with partial response. 2 months later, she had haemoptysis caused by brisk bleeding from the radiated right upper lobe. Fortunately, her bleed was self-limited. 4 months later, a rapidly enlarging renal mass was discovered and turned out to be metastatic from the lung primary. Second-line chemotherapy with docetaxel and ramucirumab did not have effects on the renal mass after 2 cycles. Despite not being eligible for a durvalumab trial because of lack of PD-L1 expression, she had a meaningful response to nivolumab. Once every 2 weeks, infusion of nivolumab resulted in rapid tumour shrinkage in multiple areas. In the next few months, she experienced a variety of side effects, some of which were potentially life-threatening. She had disease progression 9 months into treatment.

Original languageEnglish (US)
Article number215304
JournalBMJ Case Reports
Volume2016
DOIs
StatePublished - Jan 1 2016

Fingerprint

docetaxel
Immunotherapy
Survivors
Lung Neoplasms
Kidney
Drug Therapy
Squamous Cell Neoplasms
Hemoptysis
Disease Progression
Neoplasms
Radiotherapy
Hemorrhage
Lung
nivolumab
Therapeutics
ramucirumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Battling regional (stage III) lung cancer : Bumpy road of a cancer survivor in the immunotherapy age. / Hao, Zhonglin; Biddinger, Paul; Schroeder, Carsten; Tariq, Khurram.

In: BMJ Case Reports, Vol. 2016, 215304, 01.01.2016.

Research output: Contribution to journalArticle

@article{80e2e0a28e40495cb0a1e582d7e618e1,
title = "Battling regional (stage III) lung cancer: Bumpy road of a cancer survivor in the immunotherapy age",
abstract = "A 58-year-old woman, a heavy smoker, was diagnosed with stage III squamous cell lung cancer. She was treated with concurrent chemotherapy and radiotherapy, with partial response. 2 months later, she had haemoptysis caused by brisk bleeding from the radiated right upper lobe. Fortunately, her bleed was self-limited. 4 months later, a rapidly enlarging renal mass was discovered and turned out to be metastatic from the lung primary. Second-line chemotherapy with docetaxel and ramucirumab did not have effects on the renal mass after 2 cycles. Despite not being eligible for a durvalumab trial because of lack of PD-L1 expression, she had a meaningful response to nivolumab. Once every 2 weeks, infusion of nivolumab resulted in rapid tumour shrinkage in multiple areas. In the next few months, she experienced a variety of side effects, some of which were potentially life-threatening. She had disease progression 9 months into treatment.",
author = "Zhonglin Hao and Paul Biddinger and Carsten Schroeder and Khurram Tariq",
year = "2016",
month = "1",
day = "1",
doi = "10.1136/bcr-2016-215304",
language = "English (US)",
volume = "2016",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Battling regional (stage III) lung cancer

T2 - Bumpy road of a cancer survivor in the immunotherapy age

AU - Hao, Zhonglin

AU - Biddinger, Paul

AU - Schroeder, Carsten

AU - Tariq, Khurram

PY - 2016/1/1

Y1 - 2016/1/1

N2 - A 58-year-old woman, a heavy smoker, was diagnosed with stage III squamous cell lung cancer. She was treated with concurrent chemotherapy and radiotherapy, with partial response. 2 months later, she had haemoptysis caused by brisk bleeding from the radiated right upper lobe. Fortunately, her bleed was self-limited. 4 months later, a rapidly enlarging renal mass was discovered and turned out to be metastatic from the lung primary. Second-line chemotherapy with docetaxel and ramucirumab did not have effects on the renal mass after 2 cycles. Despite not being eligible for a durvalumab trial because of lack of PD-L1 expression, she had a meaningful response to nivolumab. Once every 2 weeks, infusion of nivolumab resulted in rapid tumour shrinkage in multiple areas. In the next few months, she experienced a variety of side effects, some of which were potentially life-threatening. She had disease progression 9 months into treatment.

AB - A 58-year-old woman, a heavy smoker, was diagnosed with stage III squamous cell lung cancer. She was treated with concurrent chemotherapy and radiotherapy, with partial response. 2 months later, she had haemoptysis caused by brisk bleeding from the radiated right upper lobe. Fortunately, her bleed was self-limited. 4 months later, a rapidly enlarging renal mass was discovered and turned out to be metastatic from the lung primary. Second-line chemotherapy with docetaxel and ramucirumab did not have effects on the renal mass after 2 cycles. Despite not being eligible for a durvalumab trial because of lack of PD-L1 expression, she had a meaningful response to nivolumab. Once every 2 weeks, infusion of nivolumab resulted in rapid tumour shrinkage in multiple areas. In the next few months, she experienced a variety of side effects, some of which were potentially life-threatening. She had disease progression 9 months into treatment.

UR - http://www.scopus.com/inward/record.url?scp=84978862997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978862997&partnerID=8YFLogxK

U2 - 10.1136/bcr-2016-215304

DO - 10.1136/bcr-2016-215304

M3 - Article

C2 - 27389724

AN - SCOPUS:84978862997

VL - 2016

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - 215304

ER -